Company intelligence / Profile preview

Helix Nanotechnologies

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~22
Development stage: Other

Overview

Helix Nanotechnologies has advanced its lead COVID-19 mRNA vaccine (HN-0001) into Phase I clinical trials in Australia, showing initial safety and supporting its approach of stable RNA formats with novel delivery methods. Preclinical programs target cancer immunotherapy and transplant rejection, with an expanding infectious disease pipeline.[1]

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: mRNA-based drugsNanoparticleVaccine
Industry: Biotech

Drug pipeline

1 asset

HN-0001

Unknown

Partnerships

Medicus Pharma (co-developing thermostable mRNA vaccines with microneedle delivery)

Beyond the preview

Go deeper on Helix Nanotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helix Nanotechnologies.

Explore the full profile